MedTrace Logo

Lowering InterLeukin-1 Receptor Antagonist Concentrations After TB Treatment Onset

NCT04015713 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2020-02-06

No results posted yet for this study

Summary

Despite marked improvements in the diagnosis of tuberculosis there are difficulties in diagnosing and monitoring treatment outcome among TB patients. The use of immunological biomarkers alone or in combination with other clinical parameters could predict early the response to TB treatment. The aim of this study is to demonstrate that the IL-1 receptor antagonist (IL-1Ra) concentrations significantly decrease within two weeks following TB treatment initiation in adults with active documented TB.

Conditions

Sponsors & Collaborators

  • Institut Pasteur, Cambodia

    collaborator OTHER

  • Institut National de la Santé Et de la Recherche Médicale, France

    collaborator OTHER_GOV

  • European Georges Pompidou Hospital

    collaborator OTHER

  • ANRS, Emerging Infectious Diseases

    lead OTHER_GOV

Principal Investigators

  • Laurence Weiss, MD,PhD · APHP Georges Pompidou European Hospital

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-21
Primary Completion
2021-03-31
Completion
2021-03-31

Countries

  • Cambodia
  • Côte d’Ivoire

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04015713 on ClinicalTrials.gov